Abstract

Sameer Tadipatri*, Haranath Chinthaginjala, Nishanth Goud Gadwala Vajagouni, Suryaprathap Thippeswamy Gari, Lakshmi Sampada Jayanthi and Thotlapalli Shaik Aliya Sultana

ABSTRACT

The human gut microbiome is increasingly recognized as a key player in drug metabolism, therapeutic efficacy, and disease modulation. Microbiome-targeted drug delivery (MTDD) represents a cutting-edge approach that leverages the dynamic interplay between host and microbial communities to enhance site-specific drug action and minimize systemic side effects. This review explores the rationale behind MTDD, emphasizing the role of microbial dysbiosis in diseases such as inflammatory bowel disease (IBD), metabolic disorders, and colorectal cancer. We discuss various delivery strategies, including colon-targeted systems, probiotics, synbiotics, bacteriophage therapy, and microbiota-responsive nanocarriers. Challenges such as inter-individual variability in microbiota composition, formulation stability, and regulatory ambiguity are also addressed. Advances in CRISPR technology and personalized medicine are expected to further refine MTDD platforms. This evolving field holds immense promise in revolutionizing precision therapeutics through targeted microbiome modulation.